Addition of Rituximab Significantly Improves Outcomes in Patients with Diffuse Large B-cell Lymphoma – a Single-center, Retrospective Study

Addition of Rituximab Significantly Improves Outcomes in Patients with Diffuse Large B-cell Lymphoma – a Single-center, Retrospective Study

CHOP chemotherapy has been used as a standard first-line treatment for diffuse large B-cell lymphoma since the 1970s. Phase III trials have shown that the addition of rituximab (R) to CHOP chemotherapy leads to significant improvements in response rate, progression-free survival and overall survival...

Full description

Bibliographic Details
Main Authors: David Belada, Lukáš Smolej, Monika Hrudková, Pavla Štěpánková, Alice Sýkorová, Pavel Žák, Jiří Bukač, Jaroslav Malý
Format: Article
Language:English
Published: Karolinum Press 2007-01-01
Series:Acta Medica
Subjects:
Diffuse large B-cell lymphoma
Rituximab
Non-Hodgkin’s lymphoma
Immunochemotherapy
Online Access:https://actamedica.lfhk.cuni.cz/50/2/0113/

Similar Items

Similar Items